Liu Annie, Giroux Lyne
Faculty of Medicine, The University of Toronto, Toronto, ON, Canada.
, King's College Circle, Medical Sciences Building, Toronto, ON, Canada.
Drug Saf Case Rep. 2015 Dec;2(1):1. doi: 10.1007/s40800-014-0003-z.
An 86-year-old man developed a suspected severe erythroderma during treatment with silodosin (dosage unknown) for benign prostatic enlargement. Two weeks after starting silodosin, he developed a total-body scaling dermatitis. A biopsy was planned but the patient improved at his subsequent visit and it was not taken. Silodosin was discontinued and the patient received UVB phototherapy, clobetasol ointment, and several bland and protective skin-care measures. One week after the initial presentation, the patient demonstrated improvement in his total-body scaling. Based on these findings, the patient was diagnosed with a suspected silodosin-induced erythroderma. Due to limitations in the patient's clinical history and investigations, a Naranjo assessment score was not obtainable.
一名86岁男性在使用西洛多辛(剂量不详)治疗良性前列腺增生期间出现疑似严重红皮病。开始使用西洛多辛两周后,他出现了全身性脱屑性皮炎。计划进行活检,但患者在随后的就诊时病情有所改善,因此未进行活检。停用西洛多辛后,患者接受了紫外线B光疗、氯倍他索软膏治疗以及几种温和的皮肤保护措施。在初次就诊一周后,患者全身性脱屑症状有所改善。基于这些发现,该患者被诊断为疑似西洛多辛诱发的红皮病。由于患者临床病史和检查存在局限性,无法获得纳兰霍评估评分。